Beatrice Rivalta
First author of a multicenter registry analysis comparing rapamycin and leniolisib in a rare immune disorder
Clinical Immunology and Vaccinology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
Beatrice Rivalta works in the Clinical Immunology and Vaccinology Unit at Bambino Gesù Children's Hospital in Rome.
First author of a 2026 retrospective ESID registry analysis of 95 patients with Activated PI3-Kinase-δ Syndrome (APDS), comparing real-world outcomes of rapamycin and the targeted PI3Kδ inhibitor leniolisib — finding comparable response rates for lymphoproliferation, with treatment-limiting adverse events reported only in the rapamycin group.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2026 | H | Leniolisib and rapamycin in Activated PI3-Kinase-δ-syndrome: a retrospective ESID registry-based analysis RIV2026 First author: multicenter registry of 95 APDS patients finds rapamycin and leniolisib produce comparable responses, but only rapamycin caused treatment-limiting adverse events. |
Co-authors in the Atlas 1
People with a profile here who share at least one study with Beatrice Rivalta.
ShowHide
- Maria Elena Maccari Senior author studying primary immunodeficiencies and their treatment
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.